Valuation : Sera Prognostics, Inc.

Market Cap 78.9M 67.89M 63.93M 58.25M 109M 7.51B 109M 758M 293M 3.82B 296M 290M 12.12B P/E 2026 *
-3.04x
P/E 2027 * -3.74x
Enterprise Value 78.9M 67.89M 63.93M 58.25M 109M 7.51B 109M 758M 293M 3.82B 296M 290M 12.12B EV / Sales 2026 *
351x
EV / Sales 2027 * 41x
Free-Float
85.62%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week-0.50%
Current month-5.66%
1 month-3.38%
3 months-6.10%
6 months+3.63%
Current year-32.20%
1 week 1.97
Extreme 1.97
2.06
1 month 1.89
Extreme 1.89
2.21
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
12.36
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 01/06/2023
Director of Finance/CFO 47 31/08/2026
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 74 20/04/2011
Chairman 58 08/06/2023
Director/Board Member 59 01/11/2011
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/26 Sell

Chief Executive Officer

-20,139 0.0523%
31/8/26 Free

Chief Financial Officer

287,548 0.7472%
10/7/26 Free

Director

62,657 0.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-0.50%-35.48%+29.03% 78.9M
+0.62%+0.37%+9.63%+12.82% 22.45B
-1.07%-0.39%+12.53% - 14.72B
-0.47%+1.51%+11.31%-20.43% 3.7B
+1.61%+0.91%+53.65%+34.60% 3.11B
-1.09%-3.53%-24.10%-33.83% 2.04B
-3.14%-1.07%-20.79% - 2.03B
-0.23%+0.40%-7.45%+15.31% 1.59B
-1.67%+9.08%+61.51%+104.02% 1.45B
-0.86%-1.44%-29.15%+2.38% 1.32B
Average -0.73%+0.47%+3.17%+17.99% 5.25B
Weighted average by Cap. -0.41%-0.16%+10.55%+12.06%

Financials

2026 *2027 *
Net sales 225K 194K 182K 166K 311K 21.41M 312K 2.16M 835K 10.91M 845K 827K 34.55M 1.92M 1.66M 1.56M 1.42M 2.66M 183M 2.67M 18.49M 7.14M 93.32M 7.23M 7.07M 296M
Net income -33.93M -29.2M -27.49M -25.05M -46.87M -3.23B -47.06M -326M -126M -1.64B -127M -125M -5.21B -29.1M -25.04M -23.58M -21.48M -40.2M -2.77B -40.36M -279M -108M -1.41B -109M -107M -4.47B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
09/09/26 USD 2.000 -0.50% 8,252
08/09/26 USD 2.010 -0.50% 64,074
04/09/26 USD 2.020 +2.02% 10,532
03/09/26 USD 1.980 -1.49% 15,261
02/09/26 USD 2.010 -3.37% 15,379
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.000USD
Average target price
5.500USD
Spread / Average Target
+175.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!